PMC10064459_01
Patient flow chart.. Atezo/Bev, atezolizumab plus bevacizumab.
10.1177_2050313X231164488-fig1.jpg
PMC10064459_01_10.1177_2050313X231164488-fig1.jpg
fig1-2050313X231164488
Two of 18 (11%) patients on lenvatinib alone and 4 of 15 patients (27%) on Atezo/Bev alone developed thyroid dysfunction requiring levothyroxine sodium (Figure 1). In contrast, four patients (100%) who did not develop thyroid dysfunction after treatment with lenvatinib, but developed thyroid dysfunction after treatment with Atezo/Bev, were considered in this study (Figure 1).